China Cellular Immunotherapy Limited

Yes. China Cellular Immunotherapy Limited is a legitimate Hong Kong corporation (Private company limited by shares) duly incorporated under the Companies Ordinance (Cap. 622) on 2015-07-14 (operating for 11 years). According to official registers of the Hong Kong Companies Registry (CR), the entity holds an active statutory standing of [Live / In Operation], possessing independent legal personality and full corporate capacity (Statutory verification: January 2022).

The statutory primary identifiers for China Cellular Immunotherapy Limited are: 1. Business Registration Number (BRN / Unique Business Identifier UBI): [65012058] (effective from 27 December 2023, this 8-digit number issued under Cap. 310 serves as the unified cross-departmental corporate identifier); 2. Company Registration Number (CRN): [2262790] (incorporation archive number issued under Cap. 622). Together, these dual keys uniquely lock the entity in international banking KYC and cross-border contracts.

Under the Companies Ordinance (Cap. 622) of Hong Kong, incorporated companies do not maintain a single 'legal representative' position; the Board of Directors (Section 643) exercises statutory management authority. Under the New Inspection Regime, public inspection displays directors' correspondence addresses and partially masked identification numbers. Complete current and historical directorships (Form ND2A), registered member shareholdings (Form NAR1 / Section 627), and Ultimate Beneficial Ownership (UBO / SCR under Part 12 Division 2A) are verified through official statutory filing retrieval.

Yes. Statutory indexing confirms that China Cellular Immunotherapy Limited has accumulated 10 official filing dossier(s) archived in the Hong Kong Companies Registry (latest statutory filing indexed on 2020-08-27: Form NAR1 - Annual Return (2020)). Pursuant to Section 662 of the Companies Ordinance (Cap. 622), private companies must deliver an Annual Return (Form NAR1) within 42 days after each incorporation anniversary. Available barcoded dossiers include: latest Annual Return (Form NAR1 - detailing current share capital, registered office, directors, and member shareholdings), Incorporation Form (Form NNC1), Articles of Association, and Change of Company Secretary and Director notices (Form ND2A), each bearing authentic ICRIS electronic barcode verification.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Cross-referenced across Hong Kong statutory regulatory registers (including HKMA, SFC, Companies Registry TCSP, Customs MSO/DPMS, and Insurance Authority IA), this entity holds no special statutory financial licence, operating as a general commercial corporation; 2. Judicial Screening (Litigation & Winding-Up): cross-referenced with the Hong Kong Judiciary public writs database and Official Receiver's Office (ORO) registers; no public civil action writs (HCA/DCCJ) or compulsory winding-up petitions (HCCW under Cap. 32) were found on current index records.

The statutory registered office of China Cellular Immunotherapy Limited on official record is situated at: [ROOM 3006-10, 30/F, F., CHINA RESOURCES BUILDING, 26 HARBOUR ROAD, WAN CHAI, HONG KONG]. Official registry dossiers also record 1 statutory registered office address change filing(s) (Form NR1). Pursuant to Section 658 of the Companies Ordinance (Cap. 622), every Hong Kong company must maintain a registered office in Hong Kong to which all communications and legal notices may be addressed, and file Form NR1 within 15 days of any address change. Under Section 3 of the Companies (Disclosure of Company Name and Liability Status) Regulation (Cap. 622B), the company must continuously display its registered name in legible characters at its registered office.

Under Section 127 of the Companies Ordinance (Cap. 622), Hong Kong has abolished the mandatory use of a metallic common seal; China Cellular Immunotherapy Limited (CRN: 2262790 / 8-digit BRN: 65012058) may lawfully execute a commercial contract without a common seal by having the document signed on its behalf by its sole director (for a single-director company) or by two directors / one director and the company secretary, and under Cap. 622B Section 4 must state its registered legal name on all contracts, transaction instruments, and official websites. Because commercial rubber chops are not registered with the Hong Kong Government, counterparties must retrieve the latest Annual Return (Form NAR1), director change notices (Form ND2A), and Register of Charges filings (Form NM1 under Cap. 622 s.334) from the Companies Registry to verify authorized signatory directors and asset pledges.